2 assets in Pure Red-Cell Aplasia

Therapeutic assets addressing Pure Red-Cell Aplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Pure Red-Cell Aplasia	University of Calgary	P2	CCC (53)
Sirolimus Pure Red-Cell Aplasia	University of Calgary	P2	CCC (53)